Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma

Bibliography

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60(5):277-300
   PubMed Web of Science ®Google Scholar
• Kleeff J, Michalski CW, Friess H, Buchler MW. Surgical treatment of pancreatic cancer: the role of adjuvant and multimodal therapies. Eur J Surg Oncol 2007;33(7):817-23
   Google Scholar
• Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6(1):38-51
   PubMed Web of Science ®Google Scholar
• Yang XJ, Seto E. Collaborative spirit of histone deacetylases in regulating chromatin structure and gene expression. Curr Opin Genet Dev 2003;13(2):143-53
   PubMed Web of Science ®Google Scholar
• Jenuwein T, Allis CD. Translating the histone code. Science 2001;293(5532):1074-80
   PubMed Web of Science ®Google Scholar
• Choudhary C, Kumar C, Gnad F, Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009;325(5942):834-40
   PubMed Web of Science ®Google Scholar
• Mann BS, Johnson JR, Cohen MH, FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007;12(10):1247-52
   PubMed Web of Science ®Google Scholar
• Venugopal B, Evans TR. Developing histone deacetylase inhibitors as anti-cancer therapeutics. Curr Med Chem 2011;18(11):1658-71
   Google Scholar
• Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009;10(1):32-42
   PubMed Web of Science ®Google Scholar
• Haigis MC, Guarente LP. Mammalian sirtuins–emerging roles in physiology, aging, and calorie restriction. Genes Dev 2006;20(21):2913-21
   PubMed Web of Science ®Google Scholar
• Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007;26(37):5420-32
   PubMed Web of Science ®Google Scholar
• Sengupta N, Seto E. Regulation of histone deacetylase activities. J Cell Biochem 2004;93(1):57-67
   PubMed Web of Science ®Google Scholar
• Lagger G, O'Carroll D, Rembold M, Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 2002;21(11):2672-81
   PubMed Web of Science ®Google Scholar
• Marchion DC, Bicaku E, Turner JG, HDAC2 regulates chromatin plasticity and enhances DNA vulnerability. Mol Cancer Ther 2009;8(4):794-801
   PubMed Web of Science ®Google Scholar
• Bhaskara S, Chyla BJ, Amann JM, Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Mol Cell 2008;30(1):61-72
   PubMed Web of Science ®Google Scholar
• Mariadason JM. HDACs and HDAC inhibitors in colon cancer. Epigenetics 2008;3(1):28-37
   PubMed Web of Science ®Google Scholar
• Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007;5(10):981-9
   PubMed Web of Science ®Google Scholar
• Chang S, Young BD, Li S, Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell 2006;126(2):321-34
   PubMed Web of Science ®Google Scholar
• Zhang Y, Kwon S, Yamaguchi T, Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol 2008;28(5):1688-701
   PubMed Web of Science ®Google Scholar
• Villagra A, Cheng F, Wang HW, The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol 2009;10(1):92-100
   PubMed Web of Science ®Google Scholar
• Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009;27(32):5459-68
   PubMed Web of Science ®Google Scholar
• Zhang Y, Adachi M, Kawamura R, Imai K. Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis. Cell Death Differ 2006;13(1):129-40
   PubMed Web of Science ®Google Scholar
• Zhao Y, Tan J, Zhuang L, Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci USA 2005;102(44):16090-5
   PubMed Web of Science ®Google Scholar
• Ruefli AA, Ausserlechner MJ, Bernhard D, The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 2001;98(19):10833-8
   PubMed Web of Science ®Google Scholar
• Prebet T, Vey N. Vorinostat in acute myeloid leukemia and myelodysplastic syndromes. Expert Opin Investig Drugs 2011;20(2):287-95
   PubMed Web of Science ®Google Scholar
• Insinga A, Monestiroli S, Ronzoni S, Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005;11(1):71-6
   PubMed Web of Science ®Google Scholar
• Sade H, Sarin A. Reactive oxygen species regulate quiescent T-cell apoptosis via the BH3-only proapoptotic protein BIM. Cell Death Differ 2004;11(4):416-23
   Google Scholar
• Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 2008;269(1):7-17
   PubMed Web of Science ®Google Scholar
• Kim MS, Kwon HJ, Lee YM, Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001;7(4):437-43
   PubMed Web of Science ®Google Scholar
• Ellis L, Hammers H, Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett 2009;280(2):145-53
   PubMed Web of Science ®Google Scholar
• Qian DZ, Kachhap SK, Collis SJ, Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res 2006;66(17):8814-21
   Google Scholar
• Deroanne CF, Bonjean K, Servotte S, Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 2002;21(3):427-36
   PubMed Web of Science ®Google Scholar
• Burgess AJ, Pavey S, Warrener R, Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. Mol Pharmacol 2001;60(4):828-37
   Google Scholar
• Archer SY, Meng S, Shei A. Hodin RA. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci USA 1998;95(12):6791-6
   PubMed Web of Science ®Google Scholar
• Huang BH, Laban M, Leung CH, Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 2005;12(4):395-404
   PubMed Web of Science ®Google Scholar
• Qiu L, Burgess A, Fairlie DP, Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol Biol Cell 2000;11(6):2069-83
   PubMed Web of Science ®Google Scholar
• Nakagawa M, Oda Y, Eguchi T, Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 2007;18(4):769-74
   PubMed Web of Science ®Google Scholar
• Liu T, Kuljaca S, Tee A, Marshall GM. Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev 2006;32(3):157-65
   Google Scholar
• Miyake K, Yoshizumi T, Imura S, Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. Pancreas 2008;36(3):e1-9
   PubMed Web of Science ®Google Scholar
• Fritsche P, Seidler B, Schuler S, HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut 2009;58(10):1399-409
   PubMed Web of Science ®Google Scholar
• Ouaissi M, Sielezneff I, Silvestre R, High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas. Ann Surg Oncol 2008;15(8):2318-28
   PubMed Web of Science ®Google Scholar
• Weichert W, Roske A, Gekeler V, Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 2008;98(3):604-10
   PubMed Web of Science ®Google Scholar
• Marks PA. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs 2010;19(9):1049-66
   PubMed Web of Science ®Google Scholar
• Zhu P, Martin E, Mengwasser J, Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 2004;5(5):455-63
   PubMed Web of Science ®Google Scholar
• Song J, Noh JH, Lee JH, Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS 2005;113(4):264-8
   PubMed Web of Science ®Google Scholar
• Wilson AJ, Byun DS, Popova N, Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 2006;281(19):13548-58
   PubMed Web of Science ®Google Scholar
• Weichert W, Roske A, Niesporek S, Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res 2008;14(6):1669-77
   PubMed Web of Science ®Google Scholar
• Donadelli M, Costanzo C, Faggioli L, Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells. Mol Carcinog 2003;38(2):59-69
   Google Scholar
• Kumagai T, Wakimoto N, Yin D, Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer 2007;121(3):656-65
   PubMed Web of Science ®Google Scholar
• Sato N, Ohta T, Kitagawa H, FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells. Int J Oncol 2004;24(3):679-85
   PubMed Web of Science ®Google Scholar
• Sowa Y, Orita T, Minamikawa S, Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun 1997;241(1):142-50
   Google Scholar
• Moore PS, Barbi S, Donadelli M, Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells. Biochim Biophys Acta 2004;1693(3):167-76
   Google Scholar
• Ryu JK, Lee WJ, Lee KH, SK-7041, a new histone deacetylase inhibitor, induces G2-M cell cycle arrest and apoptosis in pancreatic cancer cell lines. Cancer Lett 2006;237(1):143-54
   Google Scholar
• Arlt A, Gehrz A, Muerkoster S, Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003;22(21):3243-51
   PubMed Web of Science ®Google Scholar
• Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2(4):301-10
   PubMed Web of Science ®Google Scholar
• Weichert W, Boehm M, Gekeler V, High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. Br J Cancer 2007;97(4):523-30
   PubMed Web of Science ®Google Scholar
• Lehmann A, Denkert C, Budczies J, High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo. BMC Cancer 2009;9:395
   PubMedGoogle Scholar
• Piacentini P, Donadelli M, Costanzo C, Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. Virchows Arch 2006;448(6):797-804
   Google Scholar
• Arnold NB, Arkus N, Gunn J, Korc M. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin Cancer Res 2007;13(1):18-26
   Google Scholar
• Millward M, Price T, Townsend A, Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Investig New Drugs 2011. [Epub ahead of print]
   Google Scholar
• de Bono JS, Kristeleit R, Tolcher A, Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. Clin Cancer Res 2008;14(20):6663-73
   PubMed Web of Science ®Google Scholar
• Lassen U, Molife LR, Sorensen M, A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours. Br J Cancer 2010;103(1):12-17
   PubMed Web of Science ®Google Scholar
• Richards DA, Boehm KA, Waterhouse DM, Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study. Ann Oncol 2006;17(7):1096-102
   Google Scholar
• Munster P, Marchion D, Bicaku E, Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 2007;25(15):1979-85
   PubMed Web of Science ®Google Scholar
• Pili R, Salumbides B, Zhao M, Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. Br J Cancer 2012;106(1):77-84
   PubMed Web of Science ®Google Scholar
• Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001;1(3):181-93
   PubMed Web of Science ®Google Scholar
• Miller CP, Rudra S, Keating MJ, Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells. Blood 2009;113(18):4289-99
   Google Scholar
• Nawrocki ST, Carew JS, Pino MS, Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 2006;66(7):3773-81
   PubMed Web of Science ®Google Scholar
• Shankar S, Nall D, Tang SN, Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PLoS One 2011;6(1):e16530
   PubMed Web of Science ®Google Scholar
• Ansari D, Chen BC, Dong L, Pancreatic cancer: translational research aspects and clinical implications. World J Gastroenterol 2012;18(13):1417-24
   Web of Science ®Google Scholar
• Nalls D, Tang SN, Rodova M, Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS One 2011;6(8):e24099
   PubMed Web of Science ®Google Scholar
• Volinia S, Calin GA, Liu CG, A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006;103(7):2257-61
   PubMed Web of Science ®Google Scholar
• Sharma SV, Lee DY, Li B, A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010;141(1):69-80
   PubMed Web of Science ®Google Scholar
• Petrella A, D'Acunto CW, Rodriquez M, Effects of FR235222, a novel HDAC inhibitor, in proliferation and apoptosis of human leukaemia cell lines: role of annexin A1. Eur J Cancer 2008;44(5):740-9
   Google Scholar
• Furumai R, Matsuyama A, Kobashi N, FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2002;62(17):4916-21
   PubMed Web of Science ®Google Scholar
• Kim DH, Shin J, Kwon HJ. Psammaplin A is a natural prodrug that inhibits class I histone deacetylase. Exp Mol Med 2007;39(1):47-55
   Google Scholar
• Nian H, Delage B, Pinto JT, Dashwood RH. Allyl mercaptan, a garlic-derived organosulfur compound, inhibits histone deacetylase and enhances Sp3 binding on the P21WAF1 promoter. Carcinogenesis 2008;29(9):1816-24
   PubMed Web of Science ®Google Scholar
• Druesne N, Pagniez A, Mayeur C, Diallyl disulfide (DADS) increases histone acetylation and p21(waf1/cip1) expression in human colon tumor cell lines. Carcinogenesis 2004;25(7):1227-36
   Google Scholar
• Wang RH, Zheng Y, Kim HS, Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol Cell 2008;32(1):11-20
   PubMed Web of Science ®Google Scholar
• Link A, Balaguer F, Goel A. Cancer chemoprevention by dietary polyphenols: promising role for epigenetics. Biochem Pharmacol 2010;80(12):1771-92
   PubMed Web of Science ®Google Scholar
• Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006;7(2):131-42
   PubMed Web of Science ®Google Scholar
• Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008;14(6):818-29
   PubMed Web of Science ®Google Scholar
• Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119(6):1420-8
   PubMed Web of Science ®Google Scholar
• von Burstin J, Eser S, Paul MC, E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology 2009;137(1):361-71; 71 e1-5
   PubMed Web of Science ®Google Scholar
• Schneider G, Kramer OH, Schmid RM, Saur D. Acetylation as a transcriptional control mechanism-HDACs and HATs in pancreatic ductal adenocarcinoma. J Gastrointest Cancer 2011;42(2):85-92
   PubMedGoogle Scholar
• Massague J. TGFbeta in Cancer. Cell 2008;134(2):215-30
   PubMed Web of Science ®Google Scholar
• Shan B, Yao TP, Nguyen HT, Requirement of HDAC6 for transforming growth factor-beta1-induced epithelial-mesenchymal transition. J Biol Chem 2008;283(30):21065-73
   PubMed Web of Science ®Google Scholar
• Roberts AB, Tian F, Byfield SD, Smad3 is key to TGF-beta-mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasis. Cytokine Growth Factor Rev 2006;17(1-2):19-27
   PubMed Web of Science ®Google Scholar
• Sarkar FH, Li Y, Wang Z, Kong D. Pancreatic cancer stem cells and EMT in drug resistance and metastasis. Minerva Chir 2009;64(5):489-500
   PubMed Web of Science ®Google Scholar
• Chun SG, Zhou W, Yee NS. Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer. Cancer Biol Ther 2009;8(14):1328-39
   PubMed Web of Science ®Google Scholar
• Parmigiani RB, Xu WS, Venta-Perez G, HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation. Proc Natl Acad Sci USA 2008;105(28):9633-8
   PubMed Web of Science ®Google Scholar
• Haggarty SJ, Koeller KM, Wong JC, Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA 2003;100(8):4389-94
   PubMed Web of Science ®Google Scholar
• Bali P, Pranpat M, Bradner J, Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005;280(29):26729-34
   PubMed Web of Science ®Google Scholar
• Ogata M, Naito Z, Tanaka S, Overexpression and localization of heat shock proteins mRNA in pancreatic carcinoma. J Nihon Med Sch 2000;67(3):177-85
   Google Scholar
• Goetz MP, Toft DO, Ames MM, Erlichman C. The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 2003;14(8):1169-76
   PubMed Web of Science ®Google Scholar
• Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5(10):761-72
   PubMed Web of Science ®Google Scholar
• Basso AD, Solit DB, Chiosis G, Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 2002;277(42):39858-66
   PubMed Web of Science ®Google Scholar
• Matthaios D, Zarogoulidis P, Balgouranidou I, Molecular pathogenesis of pancreatic cancer and clinical perspectives. Oncology 2011;81(3-4):259-72
   Google Scholar
• Lang SA, Moser C, Gaumann A, Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth. Clin Cancer Res 2007;13(21):6459-68
   PubMedGoogle Scholar
• Kovacs JJ, Murphy PJ, Gaillard S, HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 2005;18(5):601-7
   PubMed Web of Science ®Google Scholar
• Chiosis G, Vilenchik M, Kim J, Solit D. Hsp90: the vulnerable chaperone. Drug Discov Today 2004;9(20):881-8
   PubMed Web of Science ®Google Scholar
• Li D, Marchenko ND, Moll UM. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ 2011;18(12):1904-13
   PubMed Web of Science ®Google Scholar
• Namdar M, Perez G, Ngo L, Marks PA. Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Proc Natl Acad Sci USA 2010;107(46):20003-8
   PubMed Web of Science ®Google Scholar
• Kawaguchi Y, Kovacs JJ, McLaurin A, The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003;115(6):727-38
   PubMed Web of Science ®Google Scholar
• Levine B. Eating oneself and uninvited guests: autophagy-related pathways in cellular defense. Cell 2005;120(2):159-62
   PubMed Web of Science ®Google Scholar
• Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature 2008;451(7182):1069-75
   PubMed Web of Science ®Google Scholar
• Lee JY, Koga H, Kawaguchi Y, HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. EMBO J 2010;29(5):969-80
   PubMed Web of Science ®Google Scholar
• Rikiishi H. Autophagic and apoptotic effects of HDAC inhibitors on cancer cells. J Biomed Biotechnol 2011;2011:830260
   Google Scholar
• Yang S, Wang X, Contino G, Pancreatic cancers require autophagy for tumor growth. Genes Dev 2011;25(7):717-29
   PubMed Web of Science ®Google Scholar
• Mujumdar N, Saluja AK. Autophagy in pancreatic cancer: an emerging mechanism of cell death. Autophagy 2010;6(7):997-8
   PubMed Web of Science ®Google Scholar
• Pardo R, Lo Re A, Archange C, Gemcitabine induces the VMP1-mediated autophagy pathway to promote apoptotic death in human pancreatic cancer cells. Pancreatology 2010;10(1):19-26
   Google Scholar
• Wong HH, Lemoine NR. Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol 2009;6(7):412-22
   PubMed Web of Science ®Google Scholar
• Matsuda K, Idezawa T, You XJ, Multiple mitogenic pathways in pancreatic cancer cells are blocked by a truncated epidermal growth factor receptor. Cancer Res 2002;62(19):5611-17
   Google Scholar
• Deribe YL, Wild P, Chandrashaker A, Regulation of epidermal growth factor receptor trafficking by lysine deacetylase HDAC6. Sci Signal 2009:2(102):ra84
   Google Scholar
• Arts J, King P, Marien A, JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clin Cancer Res 2009;15(22):6841-51
   Google Scholar
• Oki Y, Copeland A, Younes A. Clinical development of panobinostat in classical Hodgkin's lymphoma. Expert Rev Hematol 2011;4(3):245-52
   PubMed Web of Science ®Google Scholar
• Lin H, Geng X, Dang W, Molecular mechanisms associated with the antidepressant effects of the class I histone deacetylase inhibitor MS-275 in the rat ventrolateral orbital cortex. Brain Res 2012. [Epub ahead of print]
   Google Scholar
• Novotny-Diermayr V, Sangthongpitag K, Hu CY, SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Mol Cancer Ther 2010;9(3):642-52
   PubMed Web of Science ®Google Scholar
• Plumb JA, Finn PW, Williams RJ, Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2003;2(8):721-8
   PubMed Web of Science ®Google Scholar
• Golay J, Cuppini L, Leoni F, The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia 2007;21(9):1892-900
   PubMed Web of Science ®Google Scholar
• Mandl-Weber S, Meinel FG, Jankowsky R, The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells. Br J Haematol 2010;149(4):518-28
   PubMed Web of Science ®Google Scholar